RENO, Nev., July 19, 2012 /PRNewswire/ -- Lifeline Biotechnologies, Inc., (PINKSHEETS: LLBO) announces its primary affiliate and investment, First Warning Systems, Inc., has updated its website with a dynamic video. The video demonstrates the Company's core technology that identifies breast tumors at the earliest stage. Many of these tumors could develop into threatening diseases. The early identification of these tumors is many years ahead of other process capabilities (First Warning's website, firstwarningsystems.com).
Jim Holmes, Lifeline's CEO said, "This video is one of our best summaries of the First Warning Systems' capabilities and explains how and when tumors occur and how doubling times impact their development to a critical stage. These tumors are breast tissue abnormalities, some of which could develop into threatening diseases such as breast cancers. We urge all to visit the First Warning website and view this descriptive and informative video."
About Lifeline Biotechnologies Lifeline Biotechnologies, Inc. (PINKSHEETS: LLBO) founded in 1994 is based in Reno, NV. The Company has licensed its primary affiliate, First Warning Systems, Inc. The license covers Lifeline's core, patented technology, and conveys the manufacturing and marketing rights to First Warning. The device and process identifies, at very early stages of development, breast tissue abnormalities some of which are cancerous or pre-cancer. Patents have been issued based on the results of three clinical trials involving over 650 participants. The developmental clinical trials confirmed the First Warning Systems' "Proof of Concept," and its capabilities. www.lbti.com.
About First Warning Systems First Warning Systems (FWS) founded in 2008, based in Reno, NV is an affiliate of Lifeline Biotechnologies, Inc (LLBO). FWS holds the exclusive development, marketing and manufacturing license to commercialize LLBO's intellectual property for the FWS product line. The product line is a device and process for early detection of breast tissue abnormalities that provide the opportunity to deal with health risk assessment and management. Three clinical trials with over 650 participants have achieved superior outcomes when compared to other detection/diagnostic protocols. FWS is planning a final, limited clinical trial followed by a FDA 510(k) device classification submission. The 510(k) clears the FWS for commercialization. www.firstwarningsystems.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtaining financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.
For more information, contact: Jim Holmes, CEO 775-852-3222 Email: firstname.lastname@example.org
|SOURCE Lifeline Biotechnologies, Inc.|
Copyright©2012 PR Newswire.
All rights reserved